4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2013

Conditions
Leukemia
Interventions
DRUG

3 Day Thiarabine

Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3

DRUG

5 Day Thiarabine

Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Access Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01139151 - 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter